Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 22, 2004

View Archived Issues

R&D highlights from the 4th Annual Biotech In Europe Investor Forum: Glycart

Bio-E-Gel shows efficacy in the management of vasomotor symptoms after menopause

New triptolide analogues presented by Pharmagenesis

Novel trimeric contrast agents designed at Schering AG

Pfizer researchers design new protein kinase inhibitors

Tibotec describes two series of anti-HIV agents

Two series of SERMs claimed by Merck scientists

New alpha7-selective nAChR ligands identified at NeuroSearch

New melanocortin MC4 receptor ligands and their use reported by SCRAS

New p38 kinase inhibitors developed by Uriach team

Dade Behring, U. of Frankfurt and Innovectis sign cardiac marker agreement

Phase I study for INSM-18 in relapsed prostate cancer patients

Roche signs for rights to Japan Tobacco's CETP inhibitor JTT-705

Corlux enters second pivotal study for psychotic major depression

Oncolytics Biotech reports on Reolysin

PDI to promote Shionogi's Cedax

New HSS antiviral guidelines for influenza cite Tamiflu

Initial research milestone in Kinexis/Merck & Co. collaboration

Complete response submitted for Combidex

European regulatory application filed for Procleix Ultrio on Tigris system

Alefacept approved in Canada for chronic plaque psoriasis

One-year results of the MOBILE study on ibandronate in osteoporosis

Nonsteroidal SARM shows potential for osteoporosis

A testosterone patch improves sexual functioning in postmenopausal women with HSDD

Clinical evidence for the efficacy of pregabalin in GAD

Merck researchers elucidate tissue selective agonism of SARM SA-766

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...